177lu-psma-617
novartis
[' vision']
poster no. 224 presented by kambiz rahbar at #asco22 discusses safety &amp; survival outcomes in the ralu study, finding 177lu-psma treatment was well tolerated (post 223ra), with an acceptable safety profile, &amp; with similar survival outcomes to the vision study. 
Independent and international experts in GenitoUrinary (GU) oncology. Part of https://t.co/QAbKORwRcf